Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: inside layer (24), coating (68), liner (5)

Papers Trust Board - 27 July 2023

Description: Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

UHS adult major trauma guidelines

Description: Adult Major Trauma Guidelines University Hospital Southampton NHS Foundation Trust Dr Mark Baxter Director of Major Trauma, Consultant in Older Persons
Url: /Media/SUHTExtranet/WessexTraumaNetwork/UHS-adult-major-trauma-guidelines.pdf

Olaparib Tablets

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCERS OLAPARIB (tablets) This regimen may require funding. Regimen • Ovarian Cancer – Olaparib (tablets) Indication • Olaparib in its tablet
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Olaparib-Tablets.pdf

Procedure for circumference measurements of children

Description: NIHR Southampton Biomedical Research Centre The NIHR Southampton Biomedical Research Centre (BRC) has a tight quality assurance system for the writing
Url: /Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-circumference-measurements-of-children.pdf

UHS register of interests June 2025

Description: Employee Name Aarvold, Dr Alice Beatrice Rachel Aarvold, Dr Alice Beatrice Rachel Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/UHS-register-of-interests-June-2025.pdf

Avelumab-Axitinib

Description: Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable locally advanced or metastatic renal cell carcinoma (RCC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

IRD(40)-Dexamethasone_40_Ixazomib-Lenalidomide

Description: Chemotherapy Protocol Myeloma IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Indication • Ixazomib and lenalidomide
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD40-Dexamethasone-40-Ixazomib-Lenalidomide.pdf

IRD(20)-Dexamethasone_20_Ixazomib-Lenalidomide

Description: Chemotherapy Protocol Myeloma IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Indication • Ixazomib and lenalidomide
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD20-Dexamethasone-20-Ixazomib-Lenalidomide.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide Indication • Isatuximab is indicated where; - the patient has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

41 to 50 of 743

Previous … 3 4 5 6 7 … Next